CN119751422A - 化合物的盐及其晶型 - Google Patents

化合物的盐及其晶型 Download PDF

Info

Publication number
CN119751422A
CN119751422A CN202411784884.4A CN202411784884A CN119751422A CN 119751422 A CN119751422 A CN 119751422A CN 202411784884 A CN202411784884 A CN 202411784884A CN 119751422 A CN119751422 A CN 119751422A
Authority
CN
China
Prior art keywords
cancer
iii
salt
crystalline form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411784884.4A
Other languages
English (en)
Chinese (zh)
Inventor
李文姬
冯玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CN119751422A publication Critical patent/CN119751422A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202411784884.4A 2019-10-14 2020-10-13 化合物的盐及其晶型 Pending CN119751422A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910973785 2019-10-14
CN2019109737853 2019-10-14
CN202080071856.1A CN114555558B (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型
PCT/CN2020/120594 WO2021073494A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080071856.1A Division CN114555558B (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型

Publications (1)

Publication Number Publication Date
CN119751422A true CN119751422A (zh) 2025-04-04

Family

ID=75537486

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411784884.4A Pending CN119751422A (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型
CN202411778340.7A Pending CN119462616A (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型
CN202080071856.1A Active CN114555558B (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411778340.7A Pending CN119462616A (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型
CN202080071856.1A Active CN114555558B (zh) 2019-10-14 2020-10-13 化合物的盐及其晶型

Country Status (14)

Country Link
US (1) US12559472B2 (https=)
EP (1) EP4045484A4 (https=)
JP (2) JP2022552329A (https=)
KR (1) KR20220088712A (https=)
CN (3) CN119751422A (https=)
AR (1) AR120202A1 (https=)
AU (1) AU2020367905A1 (https=)
BR (1) BR112022007035A2 (https=)
CA (1) CA3154064A1 (https=)
IL (1) IL292206B2 (https=)
MX (1) MX2022004274A (https=)
TW (1) TWI895290B (https=)
UA (1) UA129777C2 (https=)
WO (1) WO2021073494A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7736357B2 (ja) * 2021-12-13 2025-09-09 アビスコ セラピューティクス カンパニー リミテッド Ｆｇｆｒ４阻害剤酸性塩およびその製造方法と使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
WO2014139145A1 (en) * 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
KR102548229B1 (ko) * 2015-04-14 2023-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 결정질 fgfr4 억제제 화합물 및 그의 용도
WO2018099451A1 (zh) 2016-12-01 2018-06-07 和记黄埔医药（上海）有限公司 化合物的晶型

Also Published As

Publication number Publication date
CN114555558A (zh) 2022-05-27
US20230121346A1 (en) 2023-04-20
TWI895290B (zh) 2025-09-01
UA129777C2 (uk) 2025-07-30
AU2020367905A1 (en) 2022-04-21
EP4045484A1 (en) 2022-08-24
IL292206B2 (en) 2026-03-01
CN114555558B (zh) 2024-12-17
US12559472B2 (en) 2026-02-24
TW202128669A (zh) 2021-08-01
AR120202A1 (es) 2022-02-02
EP4045484A4 (en) 2023-09-06
CN119462616A (zh) 2025-02-18
MX2022004274A (es) 2022-05-06
WO2021073494A1 (en) 2021-04-22
CA3154064A1 (en) 2021-04-22
JP2025143319A (ja) 2025-10-01
KR20220088712A (ko) 2022-06-28
IL292206A (en) 2022-06-01
JP2022552329A (ja) 2022-12-15
IL292206B1 (en) 2025-11-01
BR112022007035A2 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
RU2497820C2 (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US12600713B2 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
EP4399207B1 (en) Crystalline forms of quinazoline derivatives, preparation, composition and use thereof
JP2025143319A (ja) 化合物の塩及びその結晶形態
CN109593102B (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
HK40068973A (en) The salts of a compound and the crystalline forms thereof
HK40122795A (zh) 化合物的盐及其晶型
HK40120202A (zh) 化合物的盐及其晶型
HK40068973B (zh) 化合物的盐及其晶型
WO2026026904A1 (en) The crystalline forms of a compound
US20250122189A1 (en) Fgfr4 inhibitor acid salt, preparation method therefor and use thereof
WO2020011141A1 (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
EA046831B1 (ru) Соли соединения и их кристаллические формы
WO2024083183A1 (zh) 一种膦酰衍生物的盐及晶型和在医药上的用途
HK40024929B (en) Crystalline forms of a compound
CN120882709A (zh) 喹唑啉衍生物的盐型、晶型、其制备方法及应用
HK40019691A (en) The salts of a compound and the crystalline forms thereof
CN108863951A (zh) 化合物的盐及其晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40122795

Country of ref document: HK